HOME >> MEDICINE >> NEWS
Interstitial cystitis study finds limited benefit in two oral drugs

An 18-month pilot study of two commonly available treatments has shown no significant benefit in patients with interstitial cystitis (IC). The results are reported in the September issue of the Journal of Urology.

The first in a series of treatment studies planned by the IC Clinical Trials Group tested the effectiveness of pentosan polysulfate sodium (Elmiron) and hydroxyzine hydrochloride (Atarax) in 121 patients with IC. Most volunteers reported experiencing moderate pain, discomfort, and urinary frequency for at least a year before entering the study.

IC is a chronic, debilitating condition that affects about a million people, most of them women. Patients suffer pelvic, bladder, or perineal pain and the urge to urinate as often as 18 times a day. Available treatments are limited and not effective for everyone. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) initiated the Clinical Trials Group in 1998 to identify useful therapies for this devitalizing and difficult disease with no known cause and no cure. The Group is also supported by the NIH Office of Research on Women's > Health.

Elmiron and Atarax were chosen for early testing because patients prefer oral drugs and each drug has different mechanisms of action. Elmiron is the only oral drug approved by the Food and Drug Administration for IC. Doctors do not know exactly how it works, but one theory is that it may repair defects in the lining of the bladder. In some patients, mast cells are present in the tissue of the bladder wall, possibly a sign of an allergic or autoimmune reaction. Atarax, an antihistamine previously untested in a randomized, placebo-controlled trial for IC, reduces mast cell activity. Mast cell activity can cause bladder inflammation and pain and may play a part in IC.

Patients in the randomized trial received either Elmiron or Atarax, a combination of the two, or a placebo. Researchers hoped that a combinati
'"/>

Contact: Mary Harris
Mary_Harris@nih.gov
301-496-3583
NIH/National Institute of Diabetes and Digestive and Kidney Diseases
14-Aug-2003


Page: 1 2

Related medicine news :

1. First NIH clinical trial for interstitial cystitis begins
2. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
3. UMaine study looks at infants and chronic nighttime crying
4. Chronic pain treatments more effective when taken together, new study shows
5. UNC study: Most N.C. family practitioners engage in unrecognized community service
6. New study in Nature demonstrates protection against cell death during heart attack
7. UCSF study offers insight into human circadian rhythms
8. International breast cancer prevention study launches in the United States and Canada
9. UW study shows blacks and Latinos are more satisfied with physicians of the same race
10. Physicians may not be accurate in their confidence levels of their diagnoses, says Pitt study
11. Advertising by academic medical centers may risk eroding public trust, says study

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Interstitial cystitis study finds limited benefit two oral drugs

(Date:5/19/2013)... Dr. Keith Chertok now provides gum disease patients with a ... the chance of a healthier smile. Laser gum surgery ... only removes diseased gum tissue in patients, but it also ... dental implants. , LANAP uses a laser to successfully ... stimulate the healthy tissue as well as encourage new bone ...
(Date:5/19/2013)... Exciting new Skin Brushes are available from ... practice known through the ages but is a lost ... brushing, has so many benefits for our health and ... love that circulation and lymphatic systems get a boost ... is supported through Skin Brushing." , Why is Skin ...
(Date:5/19/2013)... 2013 HealthEconomics.Com , the global ... to unveil a new and exciting service: HE-Xpo: a ... powerful array of real-time communication tools to expand their ... abroad. , HE-Xpo is powered by OnStream Media’s ... and feel of being at a physical trade show, ...
(Date:5/18/2013)... Columbia (PRWEB) May 19, 2013 In “Cooking ... (published by iUniverse) , author Janet Hall Svisdahl’s new cookbook, ... recipes sure to make even the pickiest eater drool. ... pleasurably and prayerfully,” she explains. , Found within the ... a wide range of delicious recipes, from fast and simple ...
(Date:5/18/2013)... Angeles, California (PRWEB) May 18, 2013 ... surgery is an increasingly popular weight loss surgery that ... Lap Band Center wishes to give readers ... , Dr. Naim attended medical school at New York ... at New York Methodist he undertook a fellowship in ...
Breaking Medicine News(10 mins):Health News:Berkeley, CA Periodontist, Dr. Keith Chertok Now Treats Gum Disease Patients With Laser Gum Surgery Prior to Placing Dental Implants 2Health News:Exciting New Skin Brushes at Sublime Beauty® Bring Health and Beauty Benefits; Celebrities and Models Know the Secret 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 3Health News:Janet Hall Svisdahl Announces Release of ‘Cooking with Spirits for the Spirit’ 2Health News:Everything You Need to Know About Lap Band Surgery 2Health News:Everything You Need to Know About Lap Band Surgery 3
(Date:5/17/2013)... , May 17, 2013 Fuse Science, Inc. (OTCQB: ... company that is developing new, patent-pending technologies poised to redefine ... that it will hold a business update teleconference and webcast ... nd , 2013 at 4:30 PM ET. ... will host the call and will be joined by ...
(Date:5/17/2013)... , May 17, 2013 ... developer of oral drug delivery systems, announced today that ... cleared the Company,s Investigational New Drug application(IND) for ORMD-0801, ... pleased to have the FDA clearance to proceed," stated ... "The upcoming trial is a major milestone for Oramed ...
(Date:5/16/2013)... 16, 2013  PTC Therapeutics, Inc., today announced that ... with the U.S. Securities and Exchange Commission ("SEC") relating ... stock. The number of shares to be offered and ... determined. (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) ... joint book-running managers for the offering. Cowen and Company ...
Breaking Medicine Technology:Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2
Cached News: